Taghreed G Mousa1, Hanan H Omar1, Rasha Emad2, Mona I Salama2, Waleed Omar3, Mohamed Fawzy3, Howayda M Hassoba4. 1. Clinical Pathology Department, Faculty of Medicine, Suez Canal University, Ismailia, Egypt. 2. Clinical Pathology Department, Faculty of Medicine, Port Said University, Port Said, Egypt. 3. Internal Medicine Department, Nephrology Unit, Faculty of Medicine, Suez Canal University, Ismailia, Egypt. 4. Clinical Pathology Department, Faculty of Medicine, Suez Canal University, Ismailia, Egypt. hhassoba@yahoo.com.
Abstract
BACKGROUND: Systemic lupus erythematosus (SLE) is a complex autoimmune disorder of unknown etiology. Considerable evidence supports a genetic basis for susceptibility to SLE. Genetic and functional data suggested the CD40 receptor (CD40) and CD40 ligand (CD40L) as strong candidate genes for SLE. AIM: To investigate whether CD40 gene rs1883832 C/T single-nucleotide polymorphism (SNP) and/or soluble CD40 (sCD40) are associated with SLE in the Egyptian population. SUBJECTS AND METHODS: The study included a hundred SLE patients, and a fifty age- and gender-matched healthy control subjects. CD40 gene rs1883832 C/T genotyping was carried out using restriction fragment length polymorphism (RFLP), while sCD40 levels were measured by ELISA. RESULTS: CD40 rs1883832C/T genotypes (CC, TT, and CT) as well as CD40 alleles (C and T) did not differ between SLE patients and normal control (p = 0.63, 0.37, and 0.31 respectively). Though did not reach statistical significance, carriers of genotype CT had 1.5 times more chance to develop SLE compared to wild homozygous CC genotype carriers (OR 1.44), while carriers of genotype TT had ~ 2 times more chance to have SLE than CC carries (OR 1.96). Accordingly, the carriers of the T allele had ¬ 1.5 times more chance to get SLE compared to the carriers of the C allele (OR 1.4). The serum sCD40 level was significantly higher in SLE patients compared to healthy control (3.4 vs. 0.8 ng/mL, p < 0.001). In SLE patients, using CC as the reference genotype, serum sCD40 level was significantly higher in the carriers of the homozygous genotype TT (3.8 ± 1.3 vs. 2.9 ± 1.9, p = 0.0001), and T allele (3.6 ± 1.4 vs. 3.0 ± 1.5, p = 0.003). Moreover, sCD40 could discriminate SLE patients from normal subjects at a cutoff value of 0.885 ng/mL with 98% sensitivity and 96% specificity (AUC = 0.999, p < 0.001). CONCLUSIONS: The study did not prove CD40 gene (rs1883832 C/T) polymorphism as a clear risk factor of SLE in this cohort of Egyptian patients, though it was highly likely associated with the carriers of T allele. In the same context, significant high sCD40 levels were observed in the T allele carriers.
BACKGROUND:Systemic lupus erythematosus (SLE) is a complex autoimmune disorder of unknown etiology. Considerable evidence supports a genetic basis for susceptibility to SLE. Genetic and functional data suggested the CD40 receptor (CD40) and CD40 ligand (CD40L) as strong candidate genes for SLE. AIM: To investigate whether CD40 gene rs1883832 C/T single-nucleotide polymorphism (SNP) and/or soluble CD40 (sCD40) are associated with SLE in the Egyptian population. SUBJECTS AND METHODS: The study included a hundred SLEpatients, and a fifty age- and gender-matched healthy control subjects. CD40 gene rs1883832 C/T genotyping was carried out using restriction fragment length polymorphism (RFLP), while sCD40 levels were measured by ELISA. RESULTS:CD40 rs1883832C/T genotypes (CC, TT, and CT) as well as CD40 alleles (C and T) did not differ between SLEpatients and normal control (p = 0.63, 0.37, and 0.31 respectively). Though did not reach statistical significance, carriers of genotype CT had 1.5 times more chance to develop SLE compared to wild homozygous CC genotype carriers (OR 1.44), while carriers of genotype TT had ~ 2 times more chance to have SLE than CC carries (OR 1.96). Accordingly, the carriers of the T allele had ¬ 1.5 times more chance to get SLE compared to the carriers of the C allele (OR 1.4). The serum sCD40 level was significantly higher in SLEpatients compared to healthy control (3.4 vs. 0.8 ng/mL, p < 0.001). In SLEpatients, using CC as the reference genotype, serum sCD40 level was significantly higher in the carriers of the homozygous genotype TT (3.8 ± 1.3 vs. 2.9 ± 1.9, p = 0.0001), and T allele (3.6 ± 1.4 vs. 3.0 ± 1.5, p = 0.003). Moreover, sCD40 could discriminate SLEpatients from normal subjects at a cutoff value of 0.885 ng/mL with 98% sensitivity and 96% specificity (AUC = 0.999, p < 0.001). CONCLUSIONS: The study did not prove CD40 gene (rs1883832 C/T) polymorphism as a clear risk factor of SLE in this cohort of Egyptian patients, though it was highly likely associated with the carriers of T allele. In the same context, significant high sCD40 levels were observed in the T allele carriers.
Authors: P M Gaffney; W A Ortmann; S A Selby; K B Shark; T C Ockenden; K E Rohlf; N L Walgrave; W P Boyum; M L Malmgren; M E Miller; G M Kearns; R P Messner; R A King; S S Rich; T W Behrens Journal: Am J Hum Genet Date: 2000-02 Impact factor: 11.025
Authors: R Shai; F P Quismorio; L Li; O J Kwon; J Morrison; D J Wallace; C M Neuwelt; C Brautbar; W J Gauderman; C O Jacob Journal: Hum Mol Genet Date: 1999-04 Impact factor: 6.150
Authors: Yahsou Delmas; Jean-François Viallard; Anne Solanilla; Julien Villeneuve; Jean-Max Pasquet; Francis Belloc; Isabelle Dubus; Julie Déchanet-Merville; Pierre Merville; Patrick Blanco; Jean-Luc Pellegrin; Alan T Nurden; Christian Combe; Jean Ripoche Journal: Kidney Int Date: 2005-11 Impact factor: 10.612
Authors: Kerstin Büchner; Volker Henn; Michael Gräfe; Onno J de Boer; Anton E Becker; Richard A Kroczek Journal: J Pathol Date: 2003-10 Impact factor: 7.996
Authors: Dimitrios T Boumpas; Richard Furie; Susan Manzi; Gabor G Illei; Daniel J Wallace; James E Balow; Akshay Vaishnaw Journal: Arthritis Rheum Date: 2003-03
Authors: G Bertsias; J P A Ioannidis; J Boletis; S Bombardieri; R Cervera; C Dostal; J Font; I M Gilboe; F Houssiau; T Huizinga; D Isenberg; C G M Kallenberg; M Khamashta; J C Piette; M Schneider; J Smolen; G Sturfelt; A Tincani; R van Vollenhoven; C Gordon; D T Boumpas Journal: Ann Rheum Dis Date: 2007-05-15 Impact factor: 19.103